What the health-record study found
Bitar and colleagues identified 662,013 adults using semaglutide or tirzepatide, 272,343 who underwent bariatric surgery, and 158,446 who used other weight-loss medicines. The study used electronic health records for adults with obesity who did not have diabetes. Researchers matched participants for their comparisons[1].
At therapeutic doses, the recorded incidence of colorectal and pancreatic cancer was lower than in the surgery group (hazard ratios 0.72 and 0.63, respectively). Compared with other weight-loss medicines, colorectal cancer incidence was lower (hazard ratio 0.68), while pancreatic cancer showed no statistically clear difference. Neither comparison showed a clear difference in liver cancer. The analysis that included people at any dose found no statistically clear differences [1].
The survey of doses people take in practice puts the dose distinction in context. People who reach higher doses may differ from those who remain on lower doses. The cancer study compared records within dose groups, so it cannot establish that escalating the dose changes cancer risk.
What randomized trials add
A pooled analysis of 148 randomized trials with 168,875 participants found no statistically clear difference in overall cancer risk (risk ratio 0.99, 95% confidence interval 0.92 to 1.05). An exploratory prostate cancer signal did not survive correction for multiple testing [3]. These pooled results describe the outcomes captured during trial follow-up. Our review of GLP-1 use after a cancer diagnosis covers a different question about care during and after treatment. The pooled trials address cancer incidence.
For people considering a GLP-1 after a cancer diagnosis, a review of the clinical evidence highlights separate concerns such as unintended weight loss and loss of muscle during treatment [2]. Discuss the treatment goal and nutritional risks with the clinicians who manage your cancer care.